Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Unknown 2Recruiting 2Completed 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Sarcoma 1

Conditions

Breast Neoplasms 303Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × Trastuzumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 2 Completed
43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
65 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡